Publications

5677 Results

Sex Differences in Risk of Severe Adverse Events in Patients Receiving Immunotherapy, Targeted Therapy, or Chemotherapy in Cancer Clinical Trials

Authors
J Unger;R Vaidya;K Albain;M LeBlanc;L Minasian;C Gotay;NL Henry;M Fisch;S Lee;CD Blanke;D Hershman
Journal / Conference
Journal of Clinical Oncology May 1;40(13):1474-1486
Year
2022
Research Committee(s)
Cancer Care Delivery and Symptom Management and Survivorship
PMID
PMID35119908
PMC
PMC9061143

CALGB/Alliance 40603: Long-term outcomes after neoadjuvant chemotherapy with or without carboplatin and bevacizumab in triple-negative breast cancer (TNBC)

Authors
J Shepherd;K Ballman;M-Y Polley;J Campbell;C Fan;S Selitsky;A Fernandez-Martinez;J Parker;K Hoadley;Z Hu;Y Li;M Soloway;P Spears;B Singh;S Tolaney;G Somlo;E Port;C Ma;C Kuzma;E Mamounas;M Golshan;J Bellon;D Collyar;O Hahn;C Hudis;E Winer;A Partridge;T Hyslop;L Carey;C Perou;W Sikov
Journal / Conference
Journal of Clinical Oncology Jan 19;JCO2101506. doi: 10.1200/JCO.21.01506. Online ahead of print
Year
2022
Research Committee(s)
Breast
PMID
PMID35044810
Study Number(s)
CTSU/C40603

Genetically-proxied therapeutic inhibition of antihypertensive drug targets and risk of common cancers

Authors
J Yarmolinsky;V Diez-Obrero;T Richardson;M Pigeyre;J Sjaarda;G Pare;V Walker;E Vincent;V Tan;M Obon-Santacana;D Albanes;J Hampe;A Gsur;H Hampel;E Kampman;R Pai;M Jenkins;S Gallinger;W Zheng;C Amos;ILCC;PRACTICAL CONSORTIUM (Tangen);G Davey;R Martin;V Moreno
Journal / Conference
PLOS Medicine Feb 3;19(2):e1003897
Year
2022
Research Committee(s)
Prevention, Screening, and Surveillance, Prevention, Screening, and and Surveillance
PMID
PMID35113855
PMC
PMC8812899
Study Number(s)
S0000

Circulating Inflammatory Cytokines and Risk of Five Cancers: a Mendelian Randomization Analysis

Authors
E Bouras;V Karhunen;J Huang;D Gill;P Brennan;M Gunter;P Haycock;M Johansson;T Key;S Lewis;R Martin;F Mengaux;N Murphy;E Platz;R Travis;T Truong;J Yarmolinsky;M-R Jarvelin;A Dehghan;K Tsilidis;Contributor C Tangen
Journal / Conference
BMC Medicine Jan 11;20(1):3
Year
2022
Research Committee(s)
Cancer Control, Prevention, Screening, and Surveillance, Prevention, Screening, and and Surveillance
PMID
PMID35012533
PMC
PMC8750876
Study Number(s)
S0000, SWOG-9217

The relationship between Lipoprotein A and Prostate Cancer risk: A multivariable Mendelian randomization study

Authors
A Ioannidou;E Watts;A Perez-Cornago;E Platz;I Mills;T Key;R Travis;K Tsilidis;V Zuber;Contributor C Tangen
Journal / Conference
PLOS Medicine Jan 27;19(1):e1003859. doi: 10.1371/journal.pmed.1003859. eCollection 2022 Jan
Year
2022
Research Committee(s)
Cancer Control, Prevention, Screening, and Surveillance, Prevention, Screening, and and Surveillance
PMID
PMID35085228
PMC
PMC8794090
Study Number(s)
S0000, SWOG-9217

The Breast Cancer Weight Loss (BWEL) Trial (Alliance 011401): A Description of the Lifestyle Intervention

Authors
L Delahanty;T Wadden;P Goodwin;C Alfano;C Thomson;M Irwin;M Neuhouser;T Crane;E Frank;P Spears;B Gillis;D Hershman;E Paskett;W Salem;V Bernstein;V Stearns;J White;C Hudis;E Winer;L Carey;A Partridge;J Ligibel
Journal / Conference
Obesity Jan;30(1):28-38
Year
2022
Research Committee(s)
Breast
PMID
PMID34932888
Study Number(s)
CTSU/A011401

Tumor immunogenomic features determine outcomes in patients with metastatic colorectal cancer of CALGB/SWOG 80405 (Alliance) treated with standard-of-care combinations of bevacizumab and cetuximab

Authors
F Innocenti;A Yazdani;N Rashid;X Qu;F-S Ou;S Van Buren;M Bertagnolli;O Kabbarah;C Blanke;A Venook;H-J Lenz;B Vincent
Journal / Conference
Clinical Cancer Research Apr 14;28(8):1690-1700
Year
2022
Research Committee(s)
Gastrointestinal
PMID
PMID35176136
PMC
PMC9093780
Study Number(s)
CTSU/C80405

Associations Between Polymorphisms in Genes Related to Oxidative Stress and DNA Repair, Interactions With Serum Antioxidants, and Prostate Cancer Risk: Results From the Prostate Cancer Prevention Trial

Authors
Z Gong;M Platek;C Till;P Goodman;C Tangen;EA Platz;M Neuhouser;IM Thompson;R Santella;C Ambrosone
Journal / Conference
Frontiers in Oncology Jan 14;11:808715
Year
2022
Research Committee(s)
Cancer Control
PMID
PMID35096612
PMC
PMC8795906
Study Number(s)
SWOG-9217

Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score

Authors
M Huynh-Le;R Karunamuni;C Fan;L Asona;W Thompson;M Martinez;C Tangen;D Albanes;I Mills;O Andreassen;A Dale;T Seibert
Journal / Conference
Prostate Cancer and Prostatic Diseases Apr;25(4):755-761
Year
2022
Research Committee(s)
Cancer Control, Prevention, Screening, and and Surveillance
PMID
PMID35152271
PMC
PMC9372232
Study Number(s)
SWOG-9217

Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial

Authors
H Safran;K Winter;D Ilson;D Wigle;T DiPetrillo;M Haddock;T Hong;L Leichman;L Rajdev;M Resnick;L Kachnic;S Seaward;H Mamon;D Diaz Pardo;C Anderson;X Shen;A Sharma;A Katz;J Salo;K Leonard;J Moughan;C Crane
Journal / Conference
Lancet Oncology Feb;23(2):259-269
Year
2022
Research Committee(s)
Gastrointestinal
PMID
PMID35038433
Study Number(s)
CTSU/R1010